BI 3968621 / Boehringer Ingelheim - LARVOL DELTA

A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer (clinicaltrials.gov) - P1 | N=90 | Not yet recruiting | Sponsor: Boehringer Ingelheim

First-in-human • Monotherapy • New P1 trial • Oncology • Solid Tumor